Company Profile
Immuneering Stock Price, News & Analysis
- Ticker:
- IMRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.24 USD (-2.75%)
Close
Last updated: July 28, 2026
277M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, IMRX closed down 2.75% at $4.24. No new same-company headline was identified in the current news window.
Company overview
Business overview
Immuneering is an oncology company focused on deep pathway inhibition and precision cancer medicine. Its development strategy is centered on targeting signaling networks that drive tumor growth.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Immuneering sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, pathway validation, and the ability to create a differentiated targeted-cancer story.
Position Within the Biotechnology Landscape
Immuneering is a catalyst-driven oncology name whose valuation depends on early clinical execution.
Future catalysts
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a.... That matters because the company is now talking about Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now. That is the piece most likely to shape sentiment in the near term.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immuneering (IMRX)?
Immuneering (IMRX) most recently closed at 4.24 USD, a -2.75% move versus the previous session.
What is the market cap of Immuneering (IMRX)?
Immuneering currently has a market capitalization of 277M USD on BioPharmSignal.
What does Immuneering do?
Immuneering is an oncology company focused on deep pathway inhibition and precision cancer medicine. Its development strategy is centered on targeting signaling networks that drive tumor growth.
On which exchange is IMRX stock listed?
Immuneering (IMRX) is associated with NASDAQ, United States, Biopharma.
What is atebimetinib?
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a....
Which conditions is Immuneering targeting with atebimetinib?
Immuneering is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immuneering describe recent progress with atebimetinib?
What matters most for Immuneering from here is atebimetinib in first-line metastatic pancreatic cancer to be presented in a....
What is Immuneering?
Immuneering is an oncology company focused on deep pathway inhibition and precision cancer medicine.